

Guus van Dongen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/449813/publications.pdf>

Version: 2024-02-01

11
papers

437
citations

1040056

9
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

661
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 49.	1.7	14
2	Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2020-2029.	7.0	18
3	^{67}Ga -Synuclein Radiotracer Development and <i>In Vivo</i> Imaging: Recent Advancements and New Perspectives. <i>Movement Disorders</i> , 2022, 37, 936-948.	3.9	24
4	The Role of ^{89}Zr -Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals. <i>Journal of Nuclear Medicine</i> , 2021, 62, 438-445.	5.0	39
5	Improving Tumor Penetration of Antibodies and Antibody-Drug Conjugates: Taking Away the Barriers for Trojan Horses. <i>Cancer Research</i> , 2021, 81, 3956-3957.	0.9	4
6	In vivo tracking of single cells with PET. <i>Nature Biomedical Engineering</i> , 2020, 4, 765-766.	22.5	6
7	Total-Body PET and Highly Stable Chelators Together Enable Meaningful ^{89}Zr -Antibody PET Studies up to 30 Days After Injection. <i>Journal of Nuclear Medicine</i> , 2020, 61, 453-460.	5.0	66
8	First platinum(II)-based metal-organic linker technology (Lx [®]) for a plug-and-play development of antibody-drug conjugates (ADCs). <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 783-793.	5.0	14
9	The biodistribution and clearance of AlbuDAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans. <i>EJNMMI Research</i> , 2019, 9, 45.	2.5	12
10	Immuno-PET Imaging to Assess Target Engagement: Experience from ^{89}Zr -Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors. <i>Journal of Nuclear Medicine</i> , 2019, 60, 902-909.	5.0	50
11	Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. <i>Onc Immunology</i> , 2017, 6, e1277306.	4.6	190